This inventor holds 1 USPTO granted patent. Top assignee: Genesen Co., Ltd.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Xiang Ai Gui: Innovator in TLR Inhibition
Introduction
Xiang Ai Gui is a notable inventor based in Suwon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the area of toll-like receptor (TLR) inhibition. His innovative work focuses on developing solutions for diseases mediated by TLR pathways.
Latest Patents
Xiang Ai Gui holds a patent for a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8, and TLR9 signaling pathways, as well as Toll-like receptor 4 (TLR4) and TLR3. The patent, titled "Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same," describes a pharmaceutical composition aimed at preventing or treating TLR pathway-mediated diseases. This invention has shown excellent efficacy in inhibiting TLR4 and various TLR pathways, making it a promising candidate for addressing autoimmune diseases, inflammatory diseases, and degenerative neurological diseases.
Career Highlights
Xiang Ai Gui is associated with Genesen Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the realm of immunology and therapeutic interventions.
Collaborations
Xiang Ai Gui collaborates with talented professionals in his field, including Sang Dun Choi and Hyuk Kwon Kwon. These collaborations enhance the innovative potential of his research and contribute to the development of effective treatments.
Conclusion
Xiang Ai Gui's contributions to TLR inhibition represent a significant advancement in the pharmaceutical industry. His innovative approach to addressing TLR pathway-mediated diseases holds promise for improving treatment options for various health conditions.